Decipher Biosciences, Inc

Decipher Biosciences, Inc. is dedicated to advancing personalized care for urologic cancers, specifically prostate and bladder cancer, by providing tissue-based genomic tests that deliver actionable insights for treatment decision-making. Their Decipher Prostate and Decipher Bladder tests are evidence-driven tools designed to improve outcomes throughout the cancer care journey for both patients and physicians.

As the most validated tissue-based gene expression test in prostate cancer, Decipher Prostate offers significant prognostic value, even among patients undergoing active surveillance. Meanwhile, Decipher Bladder serves as the only commercially available genomic subtyping tool for bladder cancer, empowering patients and their healthcare providers to make informed treatment choices.

Generated from the website